Afatinib versus Osimertinib as First-line Treatment for Advanced *EGFR*-mutant Non-Small-Cell Lung Cancer: A Three-Year Follow-up Overall Survival Analysis

Yen-Hsiang Huang, MD, PhD[1,2,3] (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan; waynehuang0622@gmail.com)

Kuo-Hsuan Hsu, MD[1,2] (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan; vghryan@gmail.com)

Jeng-Sen Tseng, MD, PhD[1,2,3,4,5] (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan; tzeng64@gmail.com)

Po-Hsin Lee, MD[1,2,3,6,7] (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan; berry7bo@yahoo.com.tw)

I-Hung Lin, MD[1] (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan; hanklun@gmail.com)

Mu-Han Peng, MD[1] (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan; fox0714ivy@gmail.com)

Tsung-Ying Yang, MD, PhD[1,2,6,7] (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan; jonyin@gmail.com)

1. Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan)
2. Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung, Taiwan (No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan)
3. School of Medicine, College of Medicine, National Yang Ming Chiao Tung

University, Taipei, Taiwan (No. 155, Sect. 2, Linong St., Taipei, 112, Taiwan)

4. Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan (No. 145, Xingda Rd., South Dist., Taichung, 402 Taiwan)
5. Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan (No. 145, Xingda Rd., South Dist., Taichung, 402 Taiwan)
6. Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan (No. 145, Xingda Rd., South Dist., Taichung, 402 Taiwan)
7. Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung, Taiwan (No. 145, Xingda Rd., South Dist., Taichung, 402 Taiwan)

Address correspondence to:

Tsung-Ying Yang, MD, PhD

Department of Chest Medicine, Taichung Veterans General Hospital

No. 1650, Sect. 4, Taiwan Boulevard, Taichung, 407, Taiwan

E-mail: jonyin@gmail.com

Tel.: +886-4-2359-2525 ext. 3201

Fax: +886-4-2374-1320

Table S1. The clinical characteristics and demographic data (n = 128)

Characteristics	EGFR-TKI		P value*
	Afatinib, n (%)	Osimertinib, n (%)	
Age			0.582
≧65	32 (39.5)	21 (44.7)	
＜65	49 (60.5)	26 (55.3)	
Gender, n (%)			0.065
Male	40 (49.4)	15 (31.9)	
Female	41 (50.6)	32 (68.1)	
Smoking status, n (%)			0.562
Non-smokers	52 (64.2)	33 (70.2)	
Former or current-smokers	29 (35.8)	14 (29.8)	
ECOG PS, n (%)			1.000
0-1	73 (90.1)	43 (91.5)	
2-3	8 (9.9)	4 (8.5)	
Stage, n (%)			0.223
Post-operation recurrence	15 (18.5)	8 (17.0)	
Stage 4A	21 (25.9)	19 (40.4)	
Stage 4B	45 (55.6)	20 (42.6)	
Brain metastasis at baseline, n (%)			0.265
Yes	28 (34.6)	21 (44.7)	
No	53 (65.4)	26 (55.3)	
Baseline *EGFR* mutation status, n (%)			0.229
Exon 19 deletions	35 (43.2)	26 (55.3)	
Exon 21 L858R	46 (56.8)	21 (44.7)	
Objective response rate	60.5%	66.0%	0.575
Disease control rate	92.6%	85.1%	0.227

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status.
*By Fisher's exact test

Table S2. The information of 2nd sequential treatment in patients with exon 19 deletion without baseline brain metastases.

Sequential treatment	No. (%)
Afatinib	15 (100)
Osimertinib	7 (46.6%)
Platinum + pemetrexed	3 (20.0%)
Pemetrexed	3 (20.0%)
Platinum + pemetrexed + bevacizumab	1 (6.7%)
Platinum + etoposide	1 (6.7%)
Osimertinib	11 (100)
No sequential treatment	3 (27.3%)
Platinum + pemetrexed	3 (27.3%)
Osimertinib + tepotinib	2 (18.1%)
Pemetrexed	1 (9.1%)
Platinum + pemetrexed + bevacizumab	1 (9.1%)
Platinum + etoposide	1 (9.1%)

Table S3. The information of 2nd sequential treatment in overall population.

Sequential treatment	No. (%)
Afatinib	72 (100)
No sequential treatment	7 (9.7%)
Osimertinib	31 (43.1%)
Platinum + pemetrexed	13 (18.1%)
Pemetrexed	5 (6.9%)
Platinum + pemetrexed + bevacizumab	4 (5.5%)
Platinum + etoposide	4 (5.5%)
Platinum + pemetrexed + tremelimumab + durvalumab	2 (2.8%)
Platinum + pemetrexed + bevacizumab + atezolizumab	1 (1.4%)
Platinum + gemcitabine + pembrolizumab	1 (1.4%)
Osimertinib + savolitinib	1 (1.4%)
Crizotinib	1 (1.4%)
Platinum + paclitaxel	1 (1.4%)
Gemcitabine	1 (1.4%)
Osimertinib	39 (100)
No sequential treatment	9 (23.1%)
Platinum + pemetrexed	12 (30.7%)
Pemetrexed	4 (10.2%)
Platinum + pemetrexed + bevacizumab	3 (7.6%)
Platinum + etoposide	2 (5.1%)
Osimertinib + tepotinib	2 (5.1%)
Osimertinib + savotinib	1 (2.6%)
Osimertinib + Bevacizumab	1 (2.6%)
Gefitinib and capmatinib	1 (2.6%)
Crizotinib	1 (2.6%)
Paclitaxel	1 (2.6%)
TS-1	1 (2.6%)
TS-1 + gemcitabine	1 (2.6%)